We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Arcutis Biotherapeutics, Inc. (ARQT) Soars to 52-Week High, Time to Cash Out?
Read MoreHide Full Article
A strong stock as of late has been Arcutis Biotherapeutics, Inc. (ARQT - Free Report) . Shares have been marching higher, with the stock up 40.8% over the past month. The stock hit a new 52-week high of $28.96 in the previous session. Arcutis Biotherapeutics has gained 100.2% since the start of the year compared to the 4.8% move for the Zacks Medical sector and the 15.8% return for the Zacks Medical - Biomedical and Genetics industry.
What's Driving the Outperformance?
The stock has a great record of positive earnings surprises, having beaten the Zacks Consensus Estimate in each of the last four quarters. In its last earnings report on October 28, 2025, Arcutis Biotherapeutics reported EPS of $0.06 versus consensus estimate of -$0.1.
For the current fiscal year, Arcutis Biotherapeutics is expected to post earnings of -$0.24 per share on $360.24 in revenues. This represents a 79.31% change in EPS on a 83.29% change in revenues. For the next fiscal year, the company is expected to earn $0.41 per share on $470.02 in revenues. This represents a year-over-year change of 273.61% and 30.47%, respectively.
Valuation Metrics
Though Arcutis Biotherapeutics has recently hit a 52-week high, what is next for Arcutis Biotherapeutics? A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself.
On this front, we can look at the Zacks Style Scores, as they provide investors with an additional way to sort through stocks (beyond looking at the Zacks Rank of a security). The individual style scores for Value, Growth, Momentum and the combined VGM Score run from A through F. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.
Arcutis Biotherapeutics has a Value Score of D. The stock's Growth and Momentum Scores are B and C, respectively, giving the company a VGM Score of B.
Zacks Rank
We also need to look at the Zacks Rank for the stock, as this supersedes any trend on the style score front. Fortunately, Arcutis Biotherapeutics currently has a Zacks Rank of #2 (Buy) thanks to a solid earnings estimate revision trend.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Arcutis Biotherapeutics passes the test. Thus, it seems as though Arcutis Biotherapeutics shares could still be poised for more gains ahead.
How Does ARQT Stack Up to the Competition?
Shares of ARQT have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is Pharming Group N.V. Sponsored ADR (PHAR - Free Report) . PHAR has a Zacks Rank of #1 (Strong Buy) and a Value Score of D, a Growth Score of A, and a Momentum Score of A.
Earnings were strong last quarter. Pharming Group N.V. Sponsored ADR beat our consensus estimate by 100.00%, and for the current fiscal year, PHAR is expected to post earnings of $0.64 per share on revenue of $371.65 million.
Shares of Pharming Group N.V. Sponsored ADR have gained 23% over the past month, and currently trade at a forward P/E of 76.71X and a P/CF of 217.33X.
The Medical - Biomedical and Genetics industry is in the top 33% of all the industries we have in our universe, so it looks like there are some nice tailwinds for ARQT and PHAR, even beyond their own solid fundamental situation.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Arcutis Biotherapeutics, Inc. (ARQT) Soars to 52-Week High, Time to Cash Out?
A strong stock as of late has been Arcutis Biotherapeutics, Inc. (ARQT - Free Report) . Shares have been marching higher, with the stock up 40.8% over the past month. The stock hit a new 52-week high of $28.96 in the previous session. Arcutis Biotherapeutics has gained 100.2% since the start of the year compared to the 4.8% move for the Zacks Medical sector and the 15.8% return for the Zacks Medical - Biomedical and Genetics industry.
What's Driving the Outperformance?
The stock has a great record of positive earnings surprises, having beaten the Zacks Consensus Estimate in each of the last four quarters. In its last earnings report on October 28, 2025, Arcutis Biotherapeutics reported EPS of $0.06 versus consensus estimate of -$0.1.
For the current fiscal year, Arcutis Biotherapeutics is expected to post earnings of -$0.24 per share on $360.24 in revenues. This represents a 79.31% change in EPS on a 83.29% change in revenues. For the next fiscal year, the company is expected to earn $0.41 per share on $470.02 in revenues. This represents a year-over-year change of 273.61% and 30.47%, respectively.
Valuation Metrics
Though Arcutis Biotherapeutics has recently hit a 52-week high, what is next for Arcutis Biotherapeutics? A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself.
On this front, we can look at the Zacks Style Scores, as they provide investors with an additional way to sort through stocks (beyond looking at the Zacks Rank of a security). The individual style scores for Value, Growth, Momentum and the combined VGM Score run from A through F. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.
Arcutis Biotherapeutics has a Value Score of D. The stock's Growth and Momentum Scores are B and C, respectively, giving the company a VGM Score of B.
Zacks Rank
We also need to look at the Zacks Rank for the stock, as this supersedes any trend on the style score front. Fortunately, Arcutis Biotherapeutics currently has a Zacks Rank of #2 (Buy) thanks to a solid earnings estimate revision trend.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Arcutis Biotherapeutics passes the test. Thus, it seems as though Arcutis Biotherapeutics shares could still be poised for more gains ahead.
How Does ARQT Stack Up to the Competition?
Shares of ARQT have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is Pharming Group N.V. Sponsored ADR (PHAR - Free Report) . PHAR has a Zacks Rank of #1 (Strong Buy) and a Value Score of D, a Growth Score of A, and a Momentum Score of A.
Earnings were strong last quarter. Pharming Group N.V. Sponsored ADR beat our consensus estimate by 100.00%, and for the current fiscal year, PHAR is expected to post earnings of $0.64 per share on revenue of $371.65 million.
Shares of Pharming Group N.V. Sponsored ADR have gained 23% over the past month, and currently trade at a forward P/E of 76.71X and a P/CF of 217.33X.
The Medical - Biomedical and Genetics industry is in the top 33% of all the industries we have in our universe, so it looks like there are some nice tailwinds for ARQT and PHAR, even beyond their own solid fundamental situation.